Author(s)
Zhuoming Liu
Published 14 Projects
Infectious Diseases Cell Biology Inhibition COVID-19 Vacuolin 1
Sean P. J. Whelan
Published 14 Projects
Infectious Diseases Cell Biology Inhibition COVID-19 Vacuolin 1
Content
Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and possibly disrupt epidemic transmission. An anticipated correlate of such countermeasures is the level of neutralizing antibodies against the SARS-CoV-2 spike protein, yet there is no consensus as to which assay should be used for such measurements. Using an infectious molecular clone of vesicular stomatitis virus (VSV) that expresses eGFP as a marker of infection, we replaced the glycoprotein gene (G) with the spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2) and developed a high-throughput imaging-based neutralization assay at biosafety level 2. We also developed a focus reduction neutralization test with a clinical isolate of SARS-CoV-2 at biosafety level 3. We compared the neutralizing activities of monoclonal and polyclonal antibody preparations, as well as ACE2-Fc soluble decoy protein in both assays and find an exceptionally high degree of concordance. The two assays will help define correlates of protection for antibody-based countermeasures including therapeutic antibodies, immune γ-globulin or plasma preparations, and vaccines against SARS-CoV-2. Replication-competent VSV-eGFP-SARS-CoV-2 provides a rapid assay for testing inhibitors of SARS-CoV-2 mediated entry that can be performed in 7.5 hours under reduced biosafety containment. ### Competing Interest Statement M.S.D. is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, and on the Scientific Advisory Board of Moderna. D.C. and H.W.V. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. S.P.J.W. and P.W.R. have filed a disclosure with Washington University for the recombinant VSV.
More Projects
Loren Frank
13 views • 2 years ago
Global Immunotalks
390 views • 2 years ago
Laurel Yohe
2 views • 2 years ago
Global Immunotalks
130 views • 2 years ago
Jignesh H. Parmar
0 views • 1 year ago
Winston A. Haynes
0 views • 1 year ago
Noam Mazor
0 views • 1 year ago
Global Immunotalks
182 views • 2 years ago
Cem Yuksel
345 views • 2 years ago
Oscar Gonzalez-Recio
3 views • 2 years ago
Please pick a style:
Zhuoming Liu. (2021, Nov 6).Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2[Video]. Scitok. https://scitok.com/project/p/aea7dd85
Brett Case James. "Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2" Scitok, uploaded by Liu Zhuoming, 6 Nov, 2021, https://scitok.com/project/paea7dd85
Zhuoming Liu. "Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2" Scitok. (Nov 6, 2021). https://scitok.com/project/p/aea7dd85
Zhuoming Liu (Nov 6, 2021). Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 Scitok. https://scitok.com/project/p/aea7dd85
Zhuoming Liu. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2[video]. 2021 Nov 6. https://scitok.com/project/p/aea7dd85
@online{al2006link, title={ Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 }, author={ Liu, Zhuoming }, organization={Scitok}, month={ Nov }, day={ 6 }, year={ 2021 }, url = {https://scitok.com/project/p/aea7dd85}, }